MyoKardia Inc (MYOK) Gets a Buy Rating from Cantor Fitzgerald

By Carrie Williams

Cantor Fitzgerald analyst Alethia Young maintained a Buy rating on MyoKardia Inc (MYOKResearch Report) yesterday and set a price target of $90. The company’s shares closed yesterday at $47.95.

Young observed:

“: 12-month price target of $90. MYOK reported earnings this evening and an increased cash balance of ~ $630M after raising capital in 1Q19. We think that the company is well-capitalized to take advantage of its research discovery platform. One key update today was that the MAVERICK study (non-obstructive) has completed enrollment. We expect that this study will be an important catalyst for the company in 4Q19; we still think that current share levels do not reflect credit for non-obstructive. We still see additional pipeline catalysts beyond mavacamten in obstructive in 2H 2019 that keep us very positive on shares at the current level.”

According to, Young is a 4-star analyst with an average return of 6.8% and a 45.9% success rate. Young covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Spectrum Pharmaceuticals, and Vertex Pharmaceuticals.

MyoKardia Inc has an analyst consensus of Strong Buy, with a price target consensus of $85.

See today’s analyst top recommended stocks >>

The company has a one-year high of $67.79 and a one-year low of $39.01. Currently, MyoKardia Inc has an average volume of 631.9K.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.